September 19th 2024
"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP.
September 16th 2024
Dr. Saad discusses pivotal ARASENS trial for metastatic hormone-sensitive prostate cancer
March 29th 2022Urology Times interviewed co-author Fred Saad, MD, FRCS, on the importance of the ARASENS trial and the potential of triplet therapy as the future standard of care for metastatic hormone-sensitive prostate cancer.
Expert explains significance of PROpel study of olaparib/abiraterone in prostate cancer
March 24th 2022In the PROpel study, which was presented at the 2022 ASCO Genitourinary Cancers Symposium, Fred Saad, MD, FRCS, and a team of investigators evaluated the efficacy of olaparib plus abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Dr. Saad on ARASENS trial: “We now have evidence that we can do better in lethal prostate cancer”
March 21st 2022“I think we need to change the mindset that chemotherapy is a bad thing. It is a very good thing when given appropriately and when patients are more likely to get long-term benefit,” says Fred Saad, MD, FRCS.
Findings support safety, feasibility of partial-gland treatment
March 21st 2022"If adequate cancer control can be achieved by focal or partial-gland treatment, then the favorable adverse event profile could make this a preferred option for a number of men with localized intermediate-risk (and possibly selected high-risk) prostate cancer," writes Badar M. Mian, MD.
Expert Forum on Prostate Cancer Survivorship: Innovations in Sexual Health
March 16th 2022“It’s not only about prescribing medications or advising how to use it. It’s about support. It’s about checking how things are going. It’s about motivation when things are primarily not working. It’s about knowledge that things tend to improve with time, and certain functions can just recover independently,” says Marta Skrodzka, MD, PhD.
Expert Forum on Prostate Cancer Survivorship: Major Challenges
March 10th 2022“We should be really trying to raise the profile of bladder symptoms [and] functional urology issues, and educating colleagues on how to inquire about and capture that information as effectively as possible,” says Jai Seth, MD, BSc, MSc, FRCS.
How active surveillance has changed the management of prostate cancer
March 9th 2022In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kara L. Watts, MD, discusses the emergence and increasing uptake of active surveillance as a management strategy for men with prostate cancer.